Enzyme Immunoassay (EIA) > Maxim HIV-1 Limiting Antigen Avidity (LAg-Avidity) EIA, Dried Blood Spot (DBS) Kit


    Catalog Number: 92003

    Components Included:
  • Recominant gp41 HIV-1 Antigen Coated Microwell Plate
  • Sample Diluent
  • Dissociation Buffer
  • Conjugate Diluent
  • 10X Wash Solution
  • TMB Substrate
  • Stop Solution
  • Plate Sealers
  • Negative Control
  • Calibrator
  • Low Positive Control
  • High Positive Control
  • 200X Conjugate Concentrate

Order Hotline:
301-251-0800 ext. 10627
Service Hotline:
301-251-0800 ext. 10639
For International Orders:
Please contact us!

Order online

Specification


Description:

The Maxim HIV-1 Limiting Antigen-Avidity EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG.

The Maxim HIV-1 LAg-Avidity EIA uses US CDC developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized.

This product is for research use only and is not intended for use in diagnostic procedures.

Related Products

Enzyme Immunoassay (EIA)

Maxim HIV-1 Limiting Antigen Avidity (LAg-Avidity) EIA Kit - 92001

The Maxim HIV-1 Limiting Antigen-Avidity EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are...

Full Product Information

Description:

The Maxim HIV-1 Limiting Antigen-Avidity EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG.

The Maxim HIV-1 LAg-Avidity EIA uses US CDC developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized.

This product is for research use only and is not intended for use in diagnostic procedures.

Additional Information:

Product Insert
Flowchart
Video Tutorial
LAg Data Management Spreadsheet (Version 2.8)
LAg Kit Estimator

Product Inquiries

Order Via Phone

Call Order Hotline to place your order with catalog number and quantity.

Order Hotline: +1-301-251-0800 ext. 10627

Call Hotline

Service Hotline

Service Hotline: +1-301-251-0800 ext. 10639

Call Hotline

general inquiries

Email: info_mbi@mbidiagnostic.com

Fax: 301-762-1542

Send Us Your Inquiry

Monday - Friday 8:00 a.m. to 5:00 p.m. EST